Lv3
240 积分 2023-05-04 加入
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
11小时前
待确认
Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients
14天前
已完结
Anti-PD-1 Antibody (Tislelizumab) Combined with Gemcitabine and Oxaliplatin for Extranodal NK/T-cell Lymphoma Failing Asparaginase: A Multicenter Phase II Trial
1个月前
已完结
The multiple myeloma drug market
1个月前
已完结
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
1个月前
已完结
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial
2个月前
已完结
Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi
2个月前
已完结
Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib
2个月前
已完结
Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats
2个月前
已关闭
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple myeloma
3个月前
已完结
皖公网安备34019202002308
